Healthy volunteers help unlock the Body's handling of a new drug
NCT ID NCT03381547
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This trial investigates how the drug pegilodecakin is absorbed and cleared from the body when given as a single injection at different doses and in different formulations. It involves 12 healthy adults aged 18 to 55. The goal is to measure key drug levels in the blood to guide future dosing decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pegilodecakin
- What this could lead to
- If successful, this study could help determine the right dose and formulation of pegilodecakin for future trials in patients.
- What could go wrong
- This is an early-phase study in only 12 healthy people, so results may not predict effects in patients or guarantee safety or efficacy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PPD Development
Austin, Texas, 78744, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- First human trial launches for experimental PSTB100 drug
- Syringe showdown: does a prefilled device deliver drug as well as a vial?
- New edaravone tablet tested in healthy volunteers
- Healthy volunteers test new Drug's body processing
- Autoinjector or syringe? study tests how ADL-018 enters the body
- Healthy men test new oral version of edaravone in first human study